Cyltezo

Active Ingredient(s): Adalimumab-adbm
FDA Approved: * August 25, 2017
Pharm Company: * BOEHRINGER INGELHEIM
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cyltezo Overview

Adalimumab, is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).[5] It is sold under the brand name Humira, among others. It is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.[6][7][8] Use...

Read more Cyltezo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Adalimumab

Recent Cyltezo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Adalimumab-adbm
  • Injection: 10mg/0.2ml, 20mg + 0.4ml, 20mg/0.4ml, 40mg/0.8ml
  • Syringe: 40mg/0.8ml
  • Vial: 40mg/0.8ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Adalimumab-adbm or a similar ingredient: (13 results)